AbbVie's R&D spending increased 15% to $4.8B to support its drug pipeline.

{
  "signal_id": "33c37546-85d2-4d04-b69d-b200fee4e6c1",
  "signal_type": "sec-10q",
  "signal_subtype": "dataInvestment",
  "detected_at": "2026-08-04T07:05:08.351+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "detail": "The 15% year-over-year increase in R&D expenses to $4.8 billion for the first half of the year is to support all stages of the company's pipeline. This level of investment implies a significant need for clinical trial data management platforms, real-world evidence analytics, and other data-intensive research technologies.",
    "metrics": {
      "pct": 0.15,
      "timeframe": "current_year",
      "pct_context": "Year-over-year increase in R&D expenses for the six-month period",
      "dollar_context": "R&D expenses for the six months ended June 30, 2026",
      "dollar_millions": 4816
    },
    "summary": "AbbVie's R&D spending increased 15% to $4.8B to support its drug pipeline.",
    "excerpts": "Research and development (R&D) expenses increased to support all stages of the company’s pipeline assets.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "medium",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm",
    "filing_date": "2026-08-03",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Target for data vendors",
    "signal_category": "technology",
    "vendors_mentioned": [
      "RemeGen Co., Ltd.",
      "Gubra A/S",
      "ADARx Pharmaceuticals, Inc.",
      "Genentech Inc.",
      "Janssen Biotech Inc"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/33c37546-85d2-4d04-b69d-b200fee4e6c1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'